Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now
Yahoo Finance ·
While Pfizer boasts an attractive dividend yield of 6.1%, more than double that of AbbVie, long-term investors may find AbbVie to be the superior income vehicle. Year-to-date, Pfizer has registered a return exceeding 14%, slightly outperforming AbbVie's gain of over 12%. Nevertheless, a ten-year retrospective reveals a stark contrast in top-line expansion: AbbVie's revenue skyrocketed by over 138%, whereas Pfizer achieved a modest increase of just over 18%. Furthermore, AbbVie emerges as the preferred choice supported by several fundamental catalysts. Pfizer boasts a commendable track record of 16 consecutive years of quarterly dividend hikes, most recently lifting its payout by 2.3% to $0.43 per share. However, Pfizer's free-cash-flow dividend payout ratio hovers near 89%, leaving less breathing room compared to AbbVie's much safer payout ratio of only 65%.
AI 시장 분석
Pfizer is recording a high dividend yield of 6.1%, but AbbVie is evaluated as superior, showing over 138% revenue growth over the past 10 years. Pfizer's free cash flow payout ratio is 89%, higher than AbbVie's 65%, presenting a financial burden. Investors should select stocks with long-term growth potential and stable dividend capacity rather than simple high yields.
상승 영향
- Biotechnology — AbbVie highlights stable dividend growth appeal by recording over 138% revenue growth and a low free cash flow payout ratio of 65% over the past 10 years.
하락 영향
- Biotechnology — Despite Pfizer's 6.1% high dividend, its high free cash flow payout ratio of 89% raises concerns regarding long-term dividend stability and financial burden.
DYAX 전담 분석
AbbVie has secured both stock price growth momentum and dividend stability by recording an overwhelming 138% revenue growth rate and a low free cash flow payout ratio of 65% over the past 10 years. On the other hand, Pfizer is evaluated as having relatively low long-term dividend attractiveness due to its high payout ratio reaching 89% and a mere 18% 10-year revenue growth rate, despite its 6.1% high dividend.
In the bullish scenario, AbbVie could emerge as a representative value stock within the healthcare sector by steadily increasing dividends based on continuous revenue expansion. In the bearish scenario, concerns over dividend stability could grow as Pfizer's financial burden is highlighted, requiring close monitoring of future quarterly free cash flow and payout ratio trends as key indicators.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 59% · Bearish (Short) 41%
469 participants
Related News
- Citi Upgrades Chip Sector Outlook Amid Strong Semiconductor Rally
- Sector Update: Technology Equities Advance on Tuesday Afternoon
- Consumer Equities Slump During Afternoon Session
- EasyJet Faces $72 Million Lawsuit Over Abandoned Aircraft in Russia
- The Earnings Report Set to Shake the Broader Market
- Forget Occidental Petroleum. Buy This Pipeline Stock in September Instead.
